BACKGROUND: In the general population, low IGF1 has been associated with higher prevalence of cardiovascular disease and mortality. OBJECTIVE: To investigate the relationships between IGF1 levels, blood pressure (BP), and glucose tolerance (GT). SUBJECTS: Four-hundred and four subjects (200 men aged 18-80 years). EXCLUSION CRITERIA: personal history of pituitary or cardiovascular diseases; previous or current treatments with drugs interfering with BP, GT, or lipids, corticosteroids (>2 weeks), estrogens, or testosterone (>12 weeks); smoking of >15 cigarettes/day and alcohol abuse (>3 glasses of wine/day). RESULTS: Two hundred and ninety-six had normal BP (73.3%), 86 had mild (21.3%), and 22 had severe (5.4%) hypertension; 322 had normal GT (NGT (79.7%)), 53 had impaired glucose tolerance (IGT (13.1%)), 29 had diabetes mellitus (7.2%). Normotensive subjects had significantly higher IGF1 levels (0.11+/-0.94 SDS) than those with mild (-0.62+/-1.16 SDS, P<0.0001) or severe (-1.01+/-1.07 SDS, P<0.0001) hypertension. IGF1 SDS (t=-3.41, P=0.001) independently predicted systolic and diastolic BP (t=-2.77, P=0.006) values. NGT subjects had significantly higher IGF1 levels (0.13+/-0.90 SDS) than those with IGT (-0.86+/-1.14 SDS, P<0.0001) or diabetes mellitus (-1.31+/-1.13 SDS, P<0.0001). IGF1 SDS independently predicted fasting glucose (t=-3.49, P=0.0005) and homeostatic model assessment (HOMA)-R (t=-2.15, P=0.033) but not insulin (t=-1.92, P=0.055) and HOMA-beta (t=-0.19, P=0.85). CONCLUSION: IGF1 levels in the low normal range are associated with hypertension and diabetes in subjects without pituitary and cardiovascular diseases.
BACKGROUND: In the general population, low IGF1 has been associated with higher prevalence of cardiovascular disease and mortality. OBJECTIVE: To investigate the relationships between IGF1 levels, blood pressure (BP), and glucose tolerance (GT). SUBJECTS: Four-hundred and four subjects (200 men aged 18-80 years). EXCLUSION CRITERIA: personal history of pituitary or cardiovascular diseases; previous or current treatments with drugs interfering with BP, GT, or lipids, corticosteroids (>2 weeks), estrogens, or testosterone (>12 weeks); smoking of >15 cigarettes/day and alcohol abuse (>3 glasses of wine/day). RESULTS: Two hundred and ninety-six had normal BP (73.3%), 86 had mild (21.3%), and 22 had severe (5.4%) hypertension; 322 had normal GT (NGT (79.7%)), 53 had impaired glucose tolerance (IGT (13.1%)), 29 had diabetes mellitus (7.2%). Normotensive subjects had significantly higher IGF1 levels (0.11+/-0.94 SDS) than those with mild (-0.62+/-1.16 SDS, P<0.0001) or severe (-1.01+/-1.07 SDS, P<0.0001) hypertension. IGF1SDS (t=-3.41, P=0.001) independently predicted systolic and diastolic BP (t=-2.77, P=0.006) values. NGT subjects had significantly higher IGF1 levels (0.13+/-0.90 SDS) than those with IGT (-0.86+/-1.14 SDS, P<0.0001) or diabetes mellitus (-1.31+/-1.13 SDS, P<0.0001). IGF1SDS independently predicted fasting glucose (t=-3.49, P=0.0005) and homeostatic model assessment (HOMA)-R (t=-2.15, P=0.033) but not insulin (t=-1.92, P=0.055) and HOMA-beta (t=-0.19, P=0.85). CONCLUSION:IGF1 levels in the low normal range are associated with hypertension and diabetes in subjects without pituitary and cardiovascular diseases.
Authors: S Savastano; A Barbato; C Di Somma; B Guida; G Pizza; L Barrea; S Avallone; M Schiano di Cola; P Strazzullo; A Colao Journal: J Endocrinol Invest Date: 2012-07-09 Impact factor: 4.256
Authors: Hao Jiang; Juan F Toscano; Michael Schiraldi; Shlee S Song; Konrad H Schlick; Oana M Dumitrascu; Raymond Liou; Patrick D Lyden; Jianwei Pan; Renya Zhan; Jeffrey L Saver; Nestor R Gonzalez Journal: J Stroke Cerebrovasc Dis Date: 2018-11-02 Impact factor: 2.136
Authors: Christopher Grunseich; Ram Miller; Therese Swan; David J Glass; Mohamed El Mouelhi; Mara Fornaro; Olivier Petricoul; Igor Vostiar; Ronenn Roubenoff; Matthew N Meriggioli; Angela Kokkinis; Robert D Guber; Maher S Budron; John Vissing; Gianni Soraru; Tahseen Mozaffar; Albert Ludolph; John T Kissel; Kenneth H Fischbeck Journal: Lancet Neurol Date: 2018-10-15 Impact factor: 44.182
Authors: Eleonora Poggiogalle; Katie E Cherry; L Joseph Su; Sangkyu Kim; Leann Myers; David A Welsh; S Michal Jazwinski; Eric Ravussin Journal: J Am Med Dir Assoc Date: 2018-08-24 Impact factor: 4.669
Authors: O Osorio-Conles; M Guitart; J M Moreno-Navarrete; X Escoté; X Duran; J M Fernandez-Real; A M Gomez-Foix; S Fernández-Veledo; J Vendrell Journal: Mol Med Date: 2017-08-23 Impact factor: 6.354
Authors: Anilkumar K Reddy; Craig J Hartley; Thuy T Pham; Gretchen Darlington; Mark L Entman; George E Taffet Journal: J Gerontol A Biol Sci Med Sci Date: 2013-05-16 Impact factor: 6.053